Menopause review: Emerging treatments for menopausal symptoms

Vasomotor symptoms (VMS) affect 2 out of 3 women during menopause and are highly disruptive and intolerable. They exert a negative impact on a woman's physical and mental well-being and are considered a high clinical priority requiring effective treatment. Although hormone therapy remains the gold-standard treatment for hot flushes, it is associated with several side effects and contraindications. Furthermore, alternative treatments for VMS are currently less efficacious and have limited availability; therefore, a new medication to treat VMS would benefit millions of women worldwide. Neurokinin 3 receptor (NK3R) antagonists have recently been developed as novel therapeutic agents for the amelioration of VMS through their action on NK3 receptors within the hypothalamus and consequent regulation of the thermoregulatory centre. So far, three NK3R antagonists have been studied in menopausal women, which have demonstrated significant reductions in VMS frequency and severity and have shown their ability to transform patients' quality of life. (c) 2021 Published by Elsevier Ltd.

Automated summary

Vasomotor symptoms (VMS) during menopause have a significant impact on women's physical and mental well-being. Hormone therapy is the gold-standard treatment, but it has limitations. Recent development of neurokinin 3 receptor (NK3R) antagonists has shown promising results in reducing VMS and improving patients' quality of life.